Transfusions with Older Blood Linked to Adverse Events
|
By LabMedica International staff writers Posted on 11 Dec 2018 |

Image: Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours (Photo courtesy of South West London Pathology).
After a serious injury, the leading cause of death is loss of blood. Major trauma victims who receive transfusions of packed blood 22 days old or older may face increased risk of death within 24 hours.
A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. Major trauma victims can require massive transfusions of blood or blood products in a very short time. Clinical effects of stored blood toxicity include elevated risk of clot formation, infection, sepsis, organ failure and death.
A team of medical scientists led by those at the University of Alabama at Birmingham (Birmingham, Al, USA) analyzed data from the Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial. Subjects in the parent trial included critically injured adult patients admitted to 1 of 12 North American Level I trauma centers who received at least one unit of packed red blood cells (RBCs) and were predicted to require massive blood transfusion.
The primary exposure was volume of packed RBC units transfused during the first 24 hours of hospitalization, stratified by packed RBC age category: 0 to 7 days, 8 to 14 days, 15 to 21 days, and greater than or equal to 22 days. The primary outcome was 24-hour mortality. The team also evaluated the association between transfused volume of each packed RBC age category and 24-hour survival, using random-effects logistic regression, adjusting for total packed RBC volume, patient age, sex, race, mechanism of injury, Injury Severity Score, Revised Trauma Score, clinical site, and trial treatment group.
The investigators reported that the 678 patients included in the analysis received a total of 8,830 packed RBC units. One hundred patients (14.8%) died within the first 24 hours. On multivariable analysis, the number of packed RBCs greater than or equal to 22 days old was independently associated with increased 24-hour mortality (adjusted odds ratio [OR] 1.05 per packed RBC unit; OR 0.97 for 0 to 7 days old; OR 1.04 for 8 to 14 days old and OR 1.02 for 15 to 21 days old. Results of sensitivity analyses were similar only among patients who received greater than or equal to 10 packed RBC units. Packed red blood cells aged 22 days or more were associated with a 5% increase in mortality risk As more units of packed red blood cells were transfused, the likelihood of harm increased, the study found.
The authors concluded that increasing quantities of older packed RBCs are associated with increased likelihood of 24-hour mortality in trauma patients receiving massive packed RBC transfusions (≥10 units), but not in those who receive fewer than 10 units. Allison R. Jones, PhD, RN, CCNS, an Assistant Professor and lead author of the study said, “Our analysis shows that transfusions of packed red blood cell units stored for 22 days or longer are potentially toxic. To avoid adverse events or death, patients who require massive transfusions may benefit from receiving fresh stored packed red blood cells, or those stored for 14 days or less.” The study was published on November 14, 2018, in the journal Annals of Emergency Medicine.
Related Links:
University of Alabama at Birmingham
A blood transfusion is a safe, common procedure in which blood is given through an intravenous (IV) line in one of the blood vessels. Major trauma victims can require massive transfusions of blood or blood products in a very short time. Clinical effects of stored blood toxicity include elevated risk of clot formation, infection, sepsis, organ failure and death.
A team of medical scientists led by those at the University of Alabama at Birmingham (Birmingham, Al, USA) analyzed data from the Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial. Subjects in the parent trial included critically injured adult patients admitted to 1 of 12 North American Level I trauma centers who received at least one unit of packed red blood cells (RBCs) and were predicted to require massive blood transfusion.
The primary exposure was volume of packed RBC units transfused during the first 24 hours of hospitalization, stratified by packed RBC age category: 0 to 7 days, 8 to 14 days, 15 to 21 days, and greater than or equal to 22 days. The primary outcome was 24-hour mortality. The team also evaluated the association between transfused volume of each packed RBC age category and 24-hour survival, using random-effects logistic regression, adjusting for total packed RBC volume, patient age, sex, race, mechanism of injury, Injury Severity Score, Revised Trauma Score, clinical site, and trial treatment group.
The investigators reported that the 678 patients included in the analysis received a total of 8,830 packed RBC units. One hundred patients (14.8%) died within the first 24 hours. On multivariable analysis, the number of packed RBCs greater than or equal to 22 days old was independently associated with increased 24-hour mortality (adjusted odds ratio [OR] 1.05 per packed RBC unit; OR 0.97 for 0 to 7 days old; OR 1.04 for 8 to 14 days old and OR 1.02 for 15 to 21 days old. Results of sensitivity analyses were similar only among patients who received greater than or equal to 10 packed RBC units. Packed red blood cells aged 22 days or more were associated with a 5% increase in mortality risk As more units of packed red blood cells were transfused, the likelihood of harm increased, the study found.
The authors concluded that increasing quantities of older packed RBCs are associated with increased likelihood of 24-hour mortality in trauma patients receiving massive packed RBC transfusions (≥10 units), but not in those who receive fewer than 10 units. Allison R. Jones, PhD, RN, CCNS, an Assistant Professor and lead author of the study said, “Our analysis shows that transfusions of packed red blood cell units stored for 22 days or longer are potentially toxic. To avoid adverse events or death, patients who require massive transfusions may benefit from receiving fresh stored packed red blood cells, or those stored for 14 days or less.” The study was published on November 14, 2018, in the journal Annals of Emergency Medicine.
Related Links:
University of Alabama at Birmingham
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







